Skip to main content
OpenTrials
Completed

NCT Number: NCT02759003

Nightime NIV Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting

In patients with amyotrophic lateral sclerosis (ALS), non-invasive mechanical ventilation (NIV) is usually initiated in an in-hospital regime. The investigators evaluated if NIV initiated in an outpatient setting can be as effective as regards patients' adherence. The investigators also evaluated factors predicting NIV adherence and disease progression.

Completed

Looking for future studies?

Notify Me

Key information

About this study

All patients with a definite ALS diagnosis, aged > 18 years, referred to the ALS outpatient clinics of the Fondazione Salvatore Maugeri Institute of Lumezzane (Brescia) and Istituto Don Gnocchi Onlus (Milano), Italy, for respiratory functional assessments for the purpose of early initiation of NIV were considered. Patients who were in clinically stable condition and without chest infections during the previous 3 months were considered eligible for the study.

Between March 2011 and March 2014, during an outpatient visit, the patients were randomized 1:1 to two groups for NIV initiation: outpatient vs. inpatient protocol.

In both groups a diurnal NIV initiation trial was performed using pressure-support ventilators in spontaneous/timed mode with a preset tidal volume (300 ml/kg) and a fixed back-up respiratory rate (12 breaths/min). The trial included: choice of the mask, setting of ventilator pressure, at least 2 hours of NIV under supervision.

Then, the patients underwent the nighttime NIV initiation trial for a maximum of 20 nights according to the outpatient vs. inpatient protocol.

NIV trial was stopped when: 1) patients used NIV > 4 hours/night for 3 consecutive nights, 2) patients and caregivers were able to manage with ventilator, 3) patients failed after 10 consecutive educational sessions.

At enrollment (T0), the end of NIV initiation trial (T1) and after 3 months from the end of the trial (T2) respiratory function tests, blood gas analysis, and sleep study were performed.

At T1 the investigators assessed NIV acceptance (as a minimum of 3 consecutive days >4 h/night), and dyspnea symptoms by VAS (day/night), staff and patients' satisfaction.

At T2: NIV adherence (>120 h/month) and patients' satisfaction.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • consecutive patients
  • definite ALS diagnosis
  • aged > 18 years
  • in clinically stable condition
  • referred to the ALS outpatient clinics of the Fondazione Salvatore Maugeri Institute of Lumezzane (Brescia) and the Istituto Don Gnocchi Onlus (Milano), Italy for respiratory functional assessment for the purpose of early initiation of NIV
  • no chest infections during the previous 3 months.

Exclusion criteria

  • cognitive impairment
  • refusal to participate
  • severe comorbidities and contraindications to NIV (arrhythmias, cardiac failure, history of pneumothorax)
  • distance from hospital > 40 km, travel problems to attend the outpatient clinic

Treatment and study plan

Nightime NIV initiation

Procedure

In-hospital vs home

Primary outcomes

  1. Adherence as measured by the use of ventilator (hours/month)

    Time frame: At 3 months

    Evaluation after 3 months from the end of NIV initiation trial (T2)

Secondary outcomes

  1. Changes in respiratory function as assessed by spirometry

    Time frame: At 3 months

    Evaluation at 3 months from the end of NIV initiation trial (T2)

  2. Changes in dyspnea symptoms as assessed by Visual Analogue Scale

    Time frame: At 3 months

    Evaluation at 3 months from the end of NIV initiation trial (T2)

  3. Patient's questionnaire of satisfaction

    Time frame: At 20 days

    Evaluation at the end of NIV initiation trial (T1)

  4. Changes in respiratory function as assessed by Maximal inspiratory pressure/Maximal expiratory pressure

    Time frame: At 3 months

    Evaluation at 3 months from the end of NIV initiation trial (T2)

  5. Changes in respiratory function as assessed by blood gas analysis

    Time frame: At 3 months

    Evaluation at 3 months from the end of NIV initiation trial (T2)

Sponsors and collaborators

Lead sponsor

Fondazione Salvatore Maugeri

Other

Collaborators

  • Fondazione Don Carlo Gnocchi ETS

Registry information

Official study title

Nightime Noninvasive Mechanical Ventilation Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting. A Non-inferiority Study.

Important dates

Study start
2011
Primary completion
2013
Study completion
2014
First posted
May 3, 2016
Registry last updated
May 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.